What is the brand name for mirabegron (Myrbetriq)?

Brand Name for Mirabegron

The brand name for mirabegron is Myrbetriq™ in the United States. 1

Medication Overview

Mirabegron is a beta-3 adrenergic receptor agonist that is FDA-approved for:

• Treatment of overactive bladder (OAB) in adult patients with symptoms of urge urinary incontinence, urgency, and urinary frequency 1
• Neurogenic detrusor overactivity (NDO) in pediatric patients aged 3 years and older weighing 35 kg or more 1

Formulation and Dosing

Mirabegron is available as extended-release tablets in two strengths:

• 25 mg tablets
• 50 mg tablets 1

The recommended dosing regimen is:

• Starting dose: 25 mg orally once daily 2
• May increase to 50 mg once daily after 4-8 weeks if needed and tolerated 2
• Should be taken with food to reduce potential exposure-related risks 2, 1

Special Populations

Dose adjustments are required in certain patient populations:

• Severe renal impairment (eGFR 15-29 mL/min/1.73 m²): Do not exceed 25 mg daily 2, 1
• Moderate hepatic impairment (Child-Pugh Class B): Do not exceed 25 mg daily 1
• Not recommended in patients with severe hepatic impairment (Child-Pugh Class C) or end-stage renal disease 1
• No dose adjustment necessary based on age alone 2

Clinical Considerations

Mirabegron (Myrbetriq) offers several advantages over antimuscarinic agents for OAB treatment:

• Better side effect profile, particularly regarding cognitive effects 2
• Similar efficacy for symptom control 2
• Significantly lower incidence of dry mouth compared to antimuscarinic agents 3, 4

The American Urological Association recommends mirabegron as the preferred pharmacological option for elderly patients with OAB due to its favorable side effect profile 2.

Common Adverse Effects

Common adverse events associated with Myrbetriq include:

• Hypertension (requires regular blood pressure monitoring) 2, 1
• Nasopharyngitis 2, 1
• Urinary tract infection 2, 1

Important Contraindications

Myrbetriq should be avoided in patients with:

• Severe uncontrolled hypertension 2
• Severe hepatic impairment 2, 1
• End-stage renal disease 2, 1

Understanding that Myrbetriq is the brand name for mirabegron is important for healthcare providers to ensure accurate prescribing and patient education about this medication for overactive bladder management.